Effect of Chronic Supplementation of L-arginine in the Muscular Performance

Sanofi

Status and phase: Terminated; Phase 4

Conditions: Muscular Fatigue

Treatments: Drug: Placebo L-arginine aspartate (Targifor); Drug: L-arginine aspartate (Targifor)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00785811

LARAS_L_02921

Details and patient eligibility

About

The primary purpose of this study is to evaluate the effect of oral administration of L-arginine in the muscular fatigue of the quadriceps, expressed in terms of the Fatigue Resistance Factor (FRF). The secondary purpose of this study is to evaluate the effect of oral administration of L-arginine in the muscular force the quadriceps.

Enrollment: 36 patients

Sex: All

Ages: 20 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

Healthy young adults for both sex; Age between 20 and 55 years; Slight or moderate physical activity, 30 minutes per day, at least 3 times a week;

Exclusion criteria

Cardiac or pulmonary disease; Previous history of knee surgery or skeletal muscular dysfunctions in hip, knee or ankle joints; Athletic person (intensive anaerobic activity); None practiced of physical activity regularly; Medications usage

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Trial design

Primary purpose: Supportive Care

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

36 participants in 2 patient groups, including a placebo group

1

Experimental group

Description:

L-arginine aspartate (Targifor)

Treatment:

Drug: L-arginine aspartate (Targifor)

2

Placebo Comparator group

Description:

Placebo

Treatment:

Drug: Placebo L-arginine aspartate (Targifor)